NYSE: MANE

Veradermics (MANE) Stock Analysis & Forecast

Nov 13 close

$129.66−5.63 (−4.2%)

Gekko Brief

AI summaryNov 9 close

Veradermics moves this week on positive 12-month Phase 3 "302" data for VDPHL01, its extended-release oral minoxidil for male pattern hair loss, with the company reporting the highest reported hair count in the program to date. The results, covering Part B of the trial in over 500 men with mild-to-moderate pattern hair loss, were presented on an investor call. Separately, commentary has flagged the stock's valuation, noting a 267.6% year-to-date surge and a price-to-book ratio of 7.1x versus the industry average, alongside a view that the stock traded undervalued near $128.60 relative to a $170.50 fair value estimate.

The stock closes at $143.95, up 3.7%, sitting above its 50-day moving average of $118.68 and near its 52-week high of $146.57, with 52-week low at $32. One-month return stands at 10%, three-month at 32.1% and six-month at 33.1%. The GekkoIndex reads 51.8, placing it in the Neutral zone, down 2.3 over five days. Gekko Fair Value is set at $128.47, putting the current price 12% above that level.

Earnings are scheduled for 10 November 2026, zero days away, placing the report inside a typical 20-trading-day holding window; the prior quarter posted an EPS of -0.58 against a -0.65 estimate, with a -1.5% reaction. One billionaire holder and one trailblazer holder are noted. Analyst coverage from 5 firms is unanimously rated buy, with a consensus target of $170.50, implying 18.4% consensus upside. Typical 20-day price movement runs 17.1%, worth noting given the imminent earnings date.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Veradermics price vs fair value

$130.60$129.66Feb ’26Jun ’26Nov ’26
Close $129.66Gekko Fair Value $130.60

Veradermics quick facts

Market cap
$5.47B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$3.47
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
—
Volume
937,783 avg 737,024
1-year return
—
Typical daily move
±7.8%
Typical 20-day move
±17.5%
50-day average
$122.23
200-day average
—
Next earnings
—
Shares outstanding
42.20M
52-week range
$32.00$156.63

Veradermics swing-trade checklist

Veradermics scores 0 supportive, 2 mixed and 0 headwinds across the 2 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

0 supportive2 mixed0 headwinds

  • Trendno data

    No data

    Not enough price history for both moving averages.

    See the chart
  • GekkoIndexmixed

    58.1, Neutral

    Reading 58.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    0.7% below

    Price is within 5% of Gekko Fair Value (0.7% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings riskno data

    No data

    No confirmed report date on the calendar.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

Veradermics stock chart and price history

Veradermics closed at $129.66 on Nov 13, 2026, inside a 52-week range of $32.00 to $156.63.

Close50-day average200-day averageVolume
Veradermics share price, past year, with 50-day and 200-day moving averages and volume$50$75$100$150MarAprMayJunJulAugSepOctNov129.66

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+12.7%
3 months
+19.8%
6 months
+30.0%
The full MANE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MANE in Gekko

Follow Veradermics through every session

Put MANE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track MANE in GekkoFree for 7 days. No credit card required.

About Veradermics

Veradermics works on new drug candidates for skin and cosmetic conditions, with a pipeline built around treatments for pattern hair loss in both adults and children. Its best-known candidate is VDPHL01, a pill taken by mouth that does not rely on hormones and is meant for long-term management of hair loss in men and women with this condition. Alongside it, the company is developing VDMN, a dissolvable patch that uses immunotherapy to treat common warts, plus earlier programs aimed at alopecia areata, molluscum contagiosum, and atopic dermatitis.

Taken together, these programs are meant to serve dermatologists and aesthetic care providers who treat patients across age groups, as well as the broader dermatology research and clinical community.

Veradermics was founded in 2019 and is headquartered in New Haven, Connecticut. Its shares are listed on the NYSE under the ticker MANE.

Listed
NYSE
Sector
Health technology
Industry
Pharmaceuticals: major
Website
veradermics.com

Veradermics GekkoIndex: the smart money zone

Veradermics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.1, in the Neutral zone, up 4.5 points over five sessions.

010058.1Neutral

Up 4.5 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying0Not available
Accumulation32+5.5%+9.7%+12.5%+18.0%
Neutral (current zone)119+3.9%+8.8%+17.6%+36.6%
Distribution21+0.4%−1.8%+0.5%+13.5%
Selling0Not available

Average MANE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the MANE price, zone by zone.Track MANE in Gekko

Is Veradermics stock overvalued? Gekko Fair Value

Veradermics trades 0.7% below Gekko Fair Value of $130.60, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Veradermics shares are worth, recalculated every trading day.

$130.60

Gekko Fair Value, Nov 14, 2026

0.7% below fair value · About fair value

At the end of Aug 2026 the price was 32.2% below the estimate.

Gekko Fair ValueShare price, month end
$131$130Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open MANE in Gekko

Veradermics insider and Congress trading

No open-market insider purchases were filed for Veradermics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for MANE in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every MANE insider filing, plotted on the chart in Gekko.Open MANE in Gekko

Congress trades last 90 days

No trades in MANE were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for MANE, plotted on the chart in Gekko.Open MANE in Gekko

Hedge funds and billionaires quarter ended Jun 30

2of the funds Gekko tracks hold MANE.

0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Veradermics earnings: next date and track record

Veradermics beat the EPS estimate in 2 of its last 3 reports, moving 1.5% on average across the report.

2 of 3reports beat the EPS estimate
±1.5%average move across the report
0 of 3reports followed by a gain

Share-price move across each report

−2.0%Feb ’26−0.9%May ’26−1.5%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 11, 2026−$0.58
est −$0.65
+10.4%——−1.5%
May 12, 2026−$1.32
est −$0.56
−135.7%——−0.9%
Feb 25, 2026−$1.62
est −$1.81
+10.3%——−2.0%
Dec 3, 2025−$1.62————

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Veradermics stock forecast and analyst price targets

Analysts’ average 12-month price target for Veradermics is $187.33, +44.5% from the last close, from 3 firms rating the stock in the last 90 days.

$187.33consensus 12-month target, +44.5% from the last close
Low $175High $185
Buy3
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 3 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Leerink PartnersBuy, maintained$185+42.7%
Nov 10CitiBuy, maintained$175+35.0%
Nov 9CitiBuy, maintained$175+35.0%
Nov 9Leerink PartnersBuy, maintained$150+15.7%
Oct 19CitiBuy, maintained$160+23.4%
+17.6%average 20-day move after past Neutral readings
±7.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Veradermics market cap and key statistics

Veradermics’s market cap is $5.47B and revenue of $0 over the last twelve months.

Valuation

Market cap
$5.47B
EPS, TTM
−$3.47
Gekko Fair Value
$130.60

Trading

Volume
937,783
Avg volume, 20 days
737,024
52-week high
$156.63
52-week low
$32.00
Shares outstanding
42.20M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-23.1%
Quarterly earnings growth, YoY
0.0%

Risk and income

Typical daily move
±7.8%
Typical 20-day move
±17.5%

Veradermics peers

Veradermics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Veradermics stock FAQ

What is Veradermics’s market cap?

Veradermics’s market cap is $5.47B at the Nov 13, 2026 close of $129.66, with 42.20M shares outstanding.

What is the Veradermics stock forecast?

The consensus analyst 12-month price target for Veradermics is $187.33, +44.5% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Veradermics stock overvalued or undervalued?

On Gekko’s estimate Veradermics is about fair value: the Nov 13, 2026 close of $129.66 is 0.7% below Gekko Fair Value of $130.60. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

What is Veradermics’s 52-week high and low?

Veradermics’s 52-week high is $156.63 and its 52-week low is $32.00; it closed at $129.66 on Nov 13, 2026.

Is Veradermics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 2 items with data read as supportive, 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Veradermics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.